Literature DB >> 20803558

Bayesian sample size for diagnostic test studies in the absence of a gold standard: Comparing identifiable with non-identifiable models.

Nandini Dendukuri1, Patrick Bélisle, Lawrence Joseph.   

Abstract

Diagnostic tests rarely provide perfect results. The misclassification induced by imperfect sensitivities and specificities of diagnostic tests must be accounted for when planning prevalence studies or investigations into properties of new tests. The previous work has shown that applying a single imperfect test to estimate prevalence can often result in very large sample size requirements, and that sometimes even an infinite sample size is insufficient for precise estimation because the problem is non-identifiable. Adding a second test can sometimes reduce the sample size substantially, but infinite sample sizes can still occur as the problem remains non-identifiable. We investigate the further improvement possible when three diagnostic tests are to be applied. We first develop methods required for studies when three conditionally independent tests are available, using different Bayesian criteria. We then apply these criteria to prototypic scenarios, showing that large sample size reductions can occur compared to when only one or two tests are used. As the problem is now identifiable, infinite sample sizes cannot occur except in pathological situations. Finally, we relax the conditional independence assumption, demonstrating in this once again non-identifiable situation that sample sizes may substantially grow and possibly be infinite. We apply our methods to the planning of two infectious disease studies, the first designed to estimate the prevalence of Strongyloides infection, and the second relating to estimating the sensitivity of a new test for tuberculosis transmission. The much smaller sample sizes that are typically required when three as compared to one or two tests are used should encourage researchers to plan their studies using more than two diagnostic tests whenever possible. User-friendly software is available for both design and analysis stages greatly facilitating the use of these methods.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20803558     DOI: 10.1002/sim.4037

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.

Authors:  Simon Gamraoui; Guillaume Mathey; Marc Debouverie; Catherine Malaplate; René Anxionnat; Francis Guillemin; Jonathan Epstein
Journal:  J Neurol       Date:  2019-02-01       Impact factor: 4.849

Review 2.  Estimation of diagnostic test accuracy without full verification: a review of latent class methods.

Authors:  John Collins; Minh Huynh
Journal:  Stat Med       Date:  2014-06-09       Impact factor: 2.373

3.  A tutorial in estimating the prevalence of disease in humans and animals in the absence of a gold standard diagnostic.

Authors:  Fraser I Lewis; Paul R Torgerson
Journal:  Emerg Themes Epidemiol       Date:  2012-12-28

4.  Evaluation of a rapid test for the diagnosis of cholera in the absence of a gold standard.

Authors:  Anne-Laure Page; Kathryn P Alberti; Vital Mondonge; Jean Rauzier; Marie-Laure Quilici; Philippe J Guerin
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

5.  Additional Evaluation of the Point-of-Contact Circulating Cathodic Antigen Assay for Schistosoma mansoni Infection.

Authors:  Pauline N M Mwinzi; Nupur Kittur; Elizabeth Ochola; Philip J Cooper; Carl H Campbell; Charles H King; Daniel G Colley
Journal:  Front Public Health       Date:  2015-03-19

6.  Laboratory evaluation of the rapid diagnostic tests for the detection of Vibrio cholerae O1 using diarrheal samples.

Authors:  Goutam Chowdhury; Tarosi Senapati; Bhabatosh Das; Asha Kamath; Debottam Pal; Puja Bose; Arundhati Deb; Sangita Paul; Asish K Mukhopadhyay; Shanta Dutta; Thandavarayan Ramamurthy
Journal:  PLoS Negl Trop Dis       Date:  2021-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.